Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products designed to improve quality of care and address unmet medical needs.
With a focus on underserved niche markets, including hospital acute care and gastroenterology, we deliver products that serve patients in the U.S. market. Cumberland also makes its products available to patients internationally through select strategic partnerships.
We own the worldwide rights to all our brands. While Cumberland’s commercial capabilities are focused on the U.S. market, our business development team is actively pursuing opportunities to make our brands available to patients in markets around the globe.
Our primary mission is to improve upon patient care with products that offer clear advantages over existing treatments. We also strive to deliver solutions that may help reduce costs for healthcare providers and, ultimately, patients.
Cumberland Pharmaceuticals Office Locations
Cumberland Pharmaceuticals Data and Metrics
Cumberland Pharmaceuticals Financial Metrics
Revenue (Y, 2016) | 33 m |
Revenue growth (Y, 2015 - Y, 2016), % | 3570% |
Gross profit (Y, 2016) | 27.1 m |
Gross profit margin (Y, 2016), % | 82% |
Net income (Y, 2016) | (1 m) |
EBIT (Y, 2016) | (1.4 m) |
Market capitalization (28-Jun-2017) | 111 m |
Closing share price (28-Jun-2017) | 6.9 |
Cash (31-Dec-2016) | 34.5 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | Y, 2016 |
|---|---|---|---|---|
Revenue | 32 m | 36.9 m | 900 k | 33 m |
Revenue growth, % | 15% | (98%) | 3570% | |
Cost of goods sold | 5.4 m | 5.1 m | 5 m | 6 m |
Gross profit | 26.6 m | 31.8 m | (4.1 m) | 27.1 m |
Gross profit Margin, % | 83% | 86% | (452%) | 82% |
Sales and marketing expense | 14.4 m | 14.9 m | ||
R&D expense | 5.6 m | 3.4 m | ||
General and administrative expense | 9.5 m | 8.4 m | ||
Operating expense total | 35.8 m | 33.3 m | 32.4 m | 34.5 m |
EBIT | (3.8 m) | 3.6 m | 1.1 m | (1.4 m) |
EBIT margin, % | (12%) | 10% | 124% | (4%) |
Interest expense | 103.4 k | 67.1 k | 73.9 k | 106.4 k |
Interest income | 230.3 k | 251.4 k | 209.2 k | 204.7 k |
Pre tax profit | (3.7 m) | 3.7 m | 1.2 m | (1.3 m) |
Income tax expense | (1.5 m) | 1.4 m | (575.8 k) | 330.9 k |
Net Income | (2.2 m) | 2.4 m | 671.1 k | (1 m) |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 40.9 m | 39.9 m | 38.2 m | 34.5 m |
Inventories | 5.7 m | 5.6 m | 4.3 m | 5.4 m |
Current Assets | 68.7 m | 70.8 m | 67.1 m | 65.5 m |
PP&E | 880.6 k | 651 k | 536.5 k | 464.5 k |
Total Assets | 87.6 m | 95.4 m | 91.9 m | 93.4 m |
Accounts Payable | 2 m | 3.2 m | 2.9 m | 8 m |
Current Liabilities | 7.5 m | 13.7 m | 12.4 m | 14.8 m |
Retained Earnings | 16.4 m | 18.8 m | 19.5 m | 18.6 m |
Total Equity | 79.3 m | 80.8 m | 76.8 m | 73.1 m |
Financial Leverage | 1.1 x | 1.2 x | 1.2 x | 1.3 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (2.2 m) | 2.4 m | 671.1 k | (1 m) |
Depreciation and Amortization | 1.3 m | 2 m | 2.2 m | 2.4 m |
Accounts Receivable | 1.5 m | (974.3 k) | (572.4 k) | (1.3 m) |
Inventories | 495.5 k | 1.5 m | 1.3 m | (1.1 m) |
Accounts Payable | 1.5 m | 191.9 k | ||
Cash From Operating Activities | 746.1 k | 6.7 m | 5.9 m | 569.5 k |
Purchases of PP&E | (97.4 k) | (163.3 k) | (143 k) | (130.9 k) |
Cash From Investing Activities | (5.1 m) | (6 m) | (2.3 m) | (3.1 m) |
Cash From Financing Activities | (9.2 m) | (1.7 m) | (5.2 m) | (1.1 m) |
Interest Paid | 79.3 k | 28.4 k | 27.4 k | 21.9 k |
Income Taxes Paid | (129.5 k) | 17.1 k | 52.2 k | (8.4 k) |
| USD | Y, 2016 |
|---|---|
Revenue/Employee | 423.4 k |
Financial Leverage | 1.3 x |
